

KANIN[®]

LF-0132

COMPOSITION : Each mL contains**HYOSCINE BUTYLBROMIDE****20 mg****PHARMACOLOGY / PHARMACOKINETICS :**

Hyoscine Butylbromide, one of the quaternary derivatives of Hyoscine is poorly absorbed from the gastrointestinal tract and do not readily pass the blood-brain barrier unlike the other derivatives of Hyoscine. After 50 to 100 mg of Hyoscine Butylbromide was given to 6 male volunteers by mouth or by intra-intestinal infusion very little Hyoscine Butylbromide was absorbed from the upper small intestine and none appeared in the plasma.

About 2% and 90% of the dose appeared in the urine and faeces respectively.

After intravenous administration of 8 mg to 1 volunteer, 42% was eliminated in the urine and 37% in faeces.

INDICATIONS :

Kanin reduces smooth muscle tone in gastro-intestinal spasm, spasm of urinary and biliary duct.

RECOMMENDED DOSAGE, DOSAGE SCHEDULE AND ROUTE OF ADMINISTRATION :

Adults & adolescents over 12 years :

20 mg by subcutaneous, slow intravenous, intramuscular injection repeated after 30 minutes if necessary. Maximum daily dose of 100 mg should not be exceeded.

INCOMPATIBILITIES :

None known.

CONTRAINDICATIONS :

KANIN should not be administered to patients with tachycardia.

WARNINGS AND PRECAUTIONS :

KANIN can cause tachycardia, hypotension and anaphylaxis, therefore use with caution in patients with cardiac conditions such as cardiac failure, coronary heart disease or cardiac arrhythmia and patients with cardiovascular disease (e.g. acute myocardial infarction, hypertension and conditions associated with tachycardia or hypertension, and in cardiac surgery). Monitoring of these patients is advised. Emergency equipment and personnel trained in its use must be readily available.

ADVERSE EFFECTS/UNDESIRABLE EFFECTS :

Immune system disorders

Not known: anaphylactic shock including cases with fatal outcome, anaphylactic reactions.

Cardiac disorders

Common: tachycardia

USE IN PREGNANCY & LACTATION :

Antimuscarinics should generally be used during pregnancy only when the potential benefits justify the possible risks to the fetus. Although information indicating that antimuscarinics inhibit lactation and are distributed into milk is minimal and has been questioned, some manufacturers and clinicians state that these drugs should not be used in nursing women since infants may be particularly sensitive to antimuscarinic effects if drugs were present in milk.

DRUG INTERACTIONS :

Intensifies anticholinergic effects of tricyclic antidepressants, antihistamines, quinidine, amantadine and disopyramide. Enhances tachycardia effects of β adrenergic agents. Dopamine antagonists reduce effects of both drugs on GIT.

OVERDOSAGE (Symptoms and treatment) :

As for Hyoscine in general, central stimulation sometimes precedes depression, especially after large doses or in severe pain, but the main central symptom is drowsiness leading to coma, urinary retention, dry mouth, tachycardia, orthostatic hypotension, transient visual disturbance. Idiosyncratic reactions to Hyoscine may occur. However, Butylbromide dose not readily cross the blood-brain barrier, so central effects are rare. Supportive treatment is needed in case of acute poisoning.

SHELF-LIFE : 4 years**PRODUCT DESCRIPTION :**

Clear colorless sterile solution for injection.

PACK SIZE PRESENTATION : 1 x [10 x 1 mL / Amp]**STORAGE CONDITION :**

Store below 30°C. Protect from light.

MAL REG. NO.: MAL20000289AZ**DATE OF REVISION :** November 23, 2017

Manufactured by :



L.B.S. LABORATORY LTD., PART.

602 Soi Panichanant, Sukhumvit 71 Rd., Bangkok 10110, Thailand

Product Registration Holder :

HEALOL PHARMACEUTICALS SDN. BHD.

74-3, Jalan Wangsa Delima 6, KLSC Wangsa Maju,
53300 Kuala Lumpur, Malaysia.

150 mm.

FRONT

BACK

Code:	<u>R 146/17</u>
Project:	<u>Kanin inj.</u>
	<u>LF F+B</u>
Date:	<u>24-11-2017</u>
Printed Size:	<u>110x150 mm (WxH)</u>
Special Colours:	K=100